Elizabeth Doran, a 69-year-old from Ottawa, Canada, has been using GLP-1 medications like Wegovy for weight loss to manage her prediabetes and high blood pressure. However, the high cost of these medications, which can range from C$350 to C$500 monthly, has been a financial burden since her prescription isn’t covered by insurance. Recently, Canada became the first G7 country to approve a generic version of semaglutide, the active ingredient in Wegovy and Ozempic, which is expected to be available at a significantly reduced price. This development could make these medications more accessible to the three million Canadians who use them and potentially influence prices in other countries. In contrast, Americans face much higher costs for Ozempic due to patent laws that delay the introduction of generics. The approval of these generics in Canada follows similar moves in India, which have already led to price reductions by the original manufacturer, Novo Nordisk.
QUESTION: How might the availability of cheaper generic medications in Canada influence the pharmaceutical market and healthcare policies in other countries?
Why Canadians can now get cheaper generic Ozempic – and Americans can’t
